World Muscle Society Congress 2025 (WMS)

Back

The FORCE™ Platform Enables TfR1-Mediated Delivery of Exon Skipping PMO to the CNS and Resolves Anxiety in a Mouse Model of DMD (poster)

View

DYNE-251 Targets the Underlying Cause of DMD to Enable Sustained Functional Improvement in Males With DMD Mutations Amenable to Exon 51 Skipping Enrolled in the Phase 1/2 DELIVER Trial (poster)

View

DYNE-101 Targets the Underlying Cause of DM1 to Enable Multi-system Functional Improvement in the ACHIEVE Trial (poster)

View

DYNE-101 Targets the Underlying Cause of DM1 to Enable Multi-system Functional Improvement in the ACHIEVE Trial (supplement data)

View

©2026 Dyne Therapeutics, Inc. All rights reserved MED-00978. Date of preparation: July 2026.